Antibodies Market Expected To Reach USD 865.62 Billion by 2032, Growing at CAGR 13.93% To ...
Ipsen and Sutro Biopharma entered a global licensing deal for STRO-003, an ADC targeting ROR1, overexpressed in cancers, marking Ipsen's first ADC portfolio addition.United States, New York, Jan. 31, ...
American Association of Individual Investors3 天
Why Coherus BioSciences, Inc.’s (CHRS) Stock Is Down 12.59%
Coherus BioSciences, Inc.’s CHRS share price has dipped by 12.59%, which has investors questioning if this is right time to ...
American Association of Individual Investors4 天
Why Coherus BioSciences, Inc.’s (CHRS) Stock Is Up 10.66%
Coherus BioSciences, Inc.’s CHRS share price has surged by 10.66%, which has investors questioning if this is right time to sell.
BioSpace4 天
I-Mab Cuts 27% of Workforce After Pipeline Re-Prioritization
The layoffs follow an announcement in early January that I-Mab will re-prioritize resources to focus on advancing a CLDN18.2 ...
Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and ...
Takeda Canada Inc. (Takeda) is pleased to announce that Héma-Québec has added HyQvia®– (normal immunoglobulin [human] 10% and ...
Pharmabiz5 天
SEC asks SII to submit more data for approval of recombinant mAB for dengue treatment in adults
SEC asks SII to submit more data for approval of recombinant mAB for dengue treatment in adults: Our Bureau, New Delhi Wednesday, January 29, 2025, 08:00 Hrs [IST] The Subject Exp ...